KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesDeferred RevenueEmployee StatisticsGovernment Contracts Revenue By CategoryGrants And Other Revenue By CategoryGrants And Other Revenue By Category AnnualGross Margin %Gross ProfitIncome (Loss) Before Income TaxOperating Expense SegregationOpex As % Of Total Revenue %Product Sales Revenue By GeographyProduct Sales Revenue By Geography AnnualProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment, Net BreakdownPurchase Commitments AnnualRemaining Performance ObligationRemaining Performance Obligations AnnualRevenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Gross Profit (2022 - 2025)

Historic Gross Profit for Novavax (NVAX) over the last 11 years, with Q3 2025 value amounting to $48.9 million.

  • Novavax's Gross Profit rose 10486.75% to $48.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $912.8 million, marking a year-over-year increase of 6180.29%. This contributed to the annual value of $479.4 million for FY2024, which is 2508.28% down from last year.
  • Latest data reveals that Novavax reported Gross Profit of $48.9 million as of Q3 2025, which was up 10486.75% from $159.7 million recorded in Q2 2025.
  • Novavax's Gross Profit's 5-year high stood at $688.8 million during Q1 2022, with a 5-year trough of -$85.2 million in Q2 2022.
  • Moreover, its 5-year median value for Gross Profit was $175.6 million (2022), whereas its average is $221.4 million.
  • Its Gross Profit has fluctuated over the past 5 years, first plummeted by 12857.29% in 2022, then skyrocketed by 178344.97% in 2025.
  • Novavax's Gross Profit (Quarter) stood at $222.2 million in 2021, then decreased by 20.96% to $175.6 million in 2022, then decreased by 22.36% to $136.4 million in 2023, then crashed by 62.13% to $51.6 million in 2024, then dropped by 5.21% to $48.9 million in 2025.
  • Its Gross Profit was $48.9 million in Q3 2025, compared to $159.7 million in Q2 2025 and $652.5 million in Q1 2025.